Bad Drug » Revlimid
Revlimid | lenalidomide is a drug marketed by Celgene that is used to treat multiple myeloma (cancer of the plasma cells) as well as myelodysplastic syndromes (MDS), specifically 5q MDS, a condition in which myeloid blood cells are produced inefficiently, which often evolves into a severe form of anemia that requires treatment by blood transfusions.
Revlimid | lenalidomide comes with serious precautions and warnings that should be reviewed by the patient in-depth before agreeing to treatment with this drug. If you are considering treatment with Revlimid | lenalidomide, you must familiarize yourself with these risks in order to make an informed decision. Ask your doctor any questions you may have about Revlimid, and ensure that your doctor knows your complete medical history.
Revlimid’s active ingredient is lenalidomide. Inactive ingredients include:
Make sure that you are not allergic to any of Revlimid’s ingredients to prevent a severe reaction.
Revlimid | lenalidomide is only available in 28 day supplies. In order to get a refill, you must continue participation in the RevAssist program, designed to ensure that the patient continues to understand the risks of taking this medication while undergoing treatment.
Revlimid is to be taken once a day at the strength prescribed by your doctor with or without food, with a glass of water for a period of 21 days. After completion of the 21 day cycle, you will have a 7 day break, after which your next round of medication will start.
Participation in the RevAssist program is mandatory for continuing your treatment with Revlimid.
Contacting this site does not constitute an attorney - client relationship. An attorney - client relationship can be created in a written agreement.
The information included on this site is for educational purposes only. It is not intended nor implied to be a substitute for professional medical advice. The reader should always consult his or her healthcare provider. Reading the information on this website does not create a physician-patient relationship.
Copyright © © 2025 deciBel Publishing. All rights reserved.
Sitemap | Call a Lawyer
Latest FDA News
Endoscopic Vessel Harvesting (EVH) System Correction: Getinge and Maquet Cardiovascular Update Use Instructions for VasoView HemoPro 2 (VH-4000 and VH-4001) EVH Systems due to Risk for Bent or Detached Heater Wires and Silicone Peeling or Detaching During UseHemoPro EVH Systems have updated instructions related to bent/detached heater wires and peeling/detaching silicone during minimally invasive surgery.
Find us on Google+